Flunisolide

CHEMBL1512 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
434.5 g/mol
LogP
2.5
Phase
4

This inhaled corticosteroid reduces airway inflammation in asthma by suppressing the immune response in the bronchial passages. Used as a daily preventive controller medication, it does not provide immediate relief during an acute asthma attack.

分子量

434.5000 g/mol

LogP

2.50

TPSA

93.10 Ų

リピンスキーの五則

適合

治療領域

作用機序

Binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene transcription. This suppresses multiple inflammatory genes encoding cytokines, chemokines, and adhesion molecules while inducing anti-inflammatory proteins.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene transcription. This suppresses multiple inflammatory genes encoding cytokines, chemokines, and adhesion molecules while inducing anti-inflammatory proteins.

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1

InChI

InChI=1S/C24H31FO6/c1-21(2)30-19-9-14-13-8-16(25)15-7-12(27)5-6-22(15,3)20(13)17(28)10-23(14,4)24(19,31-21)18(29)11-26/h5-7,13-14,16-17,19-20,26,28H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,20+,22-,23-,24+/m0/s1

Molecular Formula

C24H31FO6

HBD / HBA

2 / 7

回転可能結合数

2

重原子数

31

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

This inhaled corticosteroid reduces airway inflammation in asthma by suppressing the immune response in the bronchial passages. Used as a daily preventive controller medication, it does not provide immediate relief during an acute asthma attack.

Binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene transcription. This suppresses multiple inflammatory genes encoding cytokines, chemokines, and adhesion molecules while inducing anti-inflammatory proteins.

Yes, Flunisolide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1512. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 82153. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.